NGNE Stock Analysis: Buy, Sell, or Hold?
NGNE - Neurogene, Inc. Common Stock
$38.64
0.32 (0.83%)
▲
5d:
+5.0%
30d:
+33.24%
90d:
+100.41%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 10, 2026
26d
Get Alerted When NGNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: NGNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: NGNE shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: NGNE is currently trading at $38.64, which is considered extended relative to its 30-day fair value range of $28.49 to $36.67.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $30.34, while resistance sits at $43.66.
Market Sentiment: NGNE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (10th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.71 (+113.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NGNE is in a strong uptrend. Immediate support is located at $30.34, while resistance sits at $43.66.
Market Sentiment: NGNE has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (10th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $81.71 (+113.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$28.49 -
$36.67
Company Quality Score
62/100
(BUY)
Options IV Signal
10th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+5.4% above its trading range)
- BULLISH: Options cheap (IV 10th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 113.2% below Wall St target ($81.71)
Trading Range Analysis
30-Day Trading Range
$28.49 -
$36.67
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$6.21
(16.1%)
Support & Resistance Levels
Support Level
$30.34
Resistance Level
$43.66
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.02
Wall Street Target
$81.71
(+113.2%)
Share & Embed Analysis
Last updated: July 14, 2026 11:43 AM ET
Data refreshes hourly during market hours. Next update: 12:43 PM
Data refreshes hourly during market hours. Next update: 12:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NGNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Christine Mikail Cvijic
SELL
4045 shares
2026-03-13
Stuart Cobb
SELL
6797 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
